# Phase 1 Study of LQT-1213 in Healthy Adults

> **NCT05759962** · PHASE1 · COMPLETED · sponsor: **Thryv Therapeutics, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Long QT Syndrome

## Interventions

- **DRUG:** LQT-1213
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05759962
- **Lead sponsor:** Thryv Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-14
- **Primary completion:** 2023-03-05
- **Final completion:** 2023-03-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05759962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05759962, "Phase 1 Study of LQT-1213 in Healthy Adults". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05759962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*